PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8863818-7 1996 Ang II-induced AT1-R mRNA destabilization is prevented by pretreatment with transcriptional inhibitors or the protein synthesis inhibitor cycloheximide, suggesting that Ang II-induced AT1-R mRNA destabilization requires the induction of an unknown factor or factors that are postulated to mediate this effect. Cycloheximide 138-151 angiotensinogen Rattus norvegicus 0-6 9531974-3 1998 VEGF mRNA levels reached a plateau within 2 h after the addition of AII and decreased after 4 h. The induction was superinduced by cycloheximide and blocked by actinomycin D. Cycloheximide 131-144 angiotensinogen Rattus norvegicus 68-71 19684181-4 2009 The protective effect of ANG II infusion to restore vascular relaxation was eliminated by coinfusion of either the EGF receptor kinase inhibitor AG-1478 (20 microg/h), the ERK1/2 inhibitor PD-98059 (10 microg/h), or the protein synthesis inhibitor cycloheximide (5 microg/h). Cycloheximide 248-261 angiotensinogen Rattus norvegicus 25-31 15254973-6 2004 Consistently, EGF inhibited AngII-stimulated formation of inositol phosphates in the presence of cycloheximide but not in the presence of actinomycin D or cytochalasin D. Cycloheximide 97-110 angiotensinogen Rattus norvegicus 28-33 9554800-4 1998 Aspirin and SQ29548 inhibited and cycloheximide and actinomycin D reduced the time-dependent enhanced response to angiotensin II in rings with endothelium from SHRs. Cycloheximide 34-47 angiotensinogen Rattus norvegicus 114-128 8863818-7 1996 Ang II-induced AT1-R mRNA destabilization is prevented by pretreatment with transcriptional inhibitors or the protein synthesis inhibitor cycloheximide, suggesting that Ang II-induced AT1-R mRNA destabilization requires the induction of an unknown factor or factors that are postulated to mediate this effect. Cycloheximide 138-151 angiotensinogen Rattus norvegicus 169-175 8754788-5 1996 A maximal increase of 2.5-fold was observed with 100 nM Ang II in an actinomycin- and cycloheximide-dependent process. Cycloheximide 86-99 angiotensinogen Rattus norvegicus 56-62 7900784-4 1995 Furthermore, this ANG II action was inhibited by both cycloheximide (1 microgram/ml) and actinomycin D (10(-6) M), indicating that synthesis of new glucose transporters is involved. Cycloheximide 54-67 angiotensinogen Rattus norvegicus 18-24 8726701-5 1996 Furthermore, the stimulatory effects of Ang II on PP2A activity were inhibited by pretreatment of cultures with pertussis toxin (PTX) (200 ng/ml; 24 h) indicating the involvement of an inhibitory G-protein; and by cycloheximide (CHX) (1 microgram/ml; 30 min) indicating a requirement for protein synthesis. Cycloheximide 214-227 angiotensinogen Rattus norvegicus 40-46 8726701-5 1996 Furthermore, the stimulatory effects of Ang II on PP2A activity were inhibited by pretreatment of cultures with pertussis toxin (PTX) (200 ng/ml; 24 h) indicating the involvement of an inhibitory G-protein; and by cycloheximide (CHX) (1 microgram/ml; 30 min) indicating a requirement for protein synthesis. Cycloheximide 229-232 angiotensinogen Rattus norvegicus 40-46 7943374-5 1994 Pretreatment of VSMC with cycloheximide (20 micrograms/ml) or actinomycin D (5 micrograms/ml) completely inhibited angiotensin II-induced alpha 1-mRNA accumulation. Cycloheximide 26-39 angiotensinogen Rattus norvegicus 115-129 8420973-3 1993 Addition of angiotensin II to serum-deprived SMC resulted in a marked induction of PTHrP mRNA by 2 h, with a peak (6-10-fold) at 4-6 h. Angiotensin II effects on PTHrP gene expression were inhibited by saralasin, an angiotensin II receptor antagonist, and blocked by actinomycin D and cycloheximide, suggesting a requirement for gene transcription and protein synthesis. Cycloheximide 285-298 angiotensinogen Rattus norvegicus 12-26 8420973-3 1993 Addition of angiotensin II to serum-deprived SMC resulted in a marked induction of PTHrP mRNA by 2 h, with a peak (6-10-fold) at 4-6 h. Angiotensin II effects on PTHrP gene expression were inhibited by saralasin, an angiotensin II receptor antagonist, and blocked by actinomycin D and cycloheximide, suggesting a requirement for gene transcription and protein synthesis. Cycloheximide 285-298 angiotensinogen Rattus norvegicus 136-150 1558167-11 1992 The levels of GDH mRNA are also increased by treating cells with adenosine 3",5"-cyclic monophosphate, epinephrine, triiodothyronine, or retinoic acid, whereas treatment with angiotensin II, vasopressin, phorbol 12-myristate 13-acetate, or cycloheximide did not produce an increase. Cycloheximide 240-253 angiotensinogen Rattus norvegicus 175-189 1618554-5 1992 Increases in angiotensin II receptors were dependent on protein synthesis as evidenced by the time dependency of upregulation and inhibition by cycloheximide. Cycloheximide 144-157 angiotensinogen Rattus norvegicus 13-27 35118791-7 2022 Cycloheximide, but not actinomycin D, abolished LC3 II and total LC3 increase elicited by Ang II in RASMCs. Cycloheximide 0-13 angiotensinogen Rattus norvegicus 90-96 35118791-8 2022 In A7r5 cells, cycloheximide prevented the Ang II-mediated increase of LC3 I and total LC3, but not LC3 II. Cycloheximide 15-28 angiotensinogen Rattus norvegicus 43-49 3955081-2 1986 The hepatocyte preparation released angiotensinogen at a basal rate of 50-120 pmol/g wet weight per h. Release was linear with time for at least 4 h. Angiotensinogen secretion was reduced in the presence of actinomycin D, and inhibited by cycloheximide, puromycin, colchicine and vinblastine. Cycloheximide 239-252 angiotensinogen Rattus norvegicus 150-165 2912130-8 1989 The increase in [125I]ANG II-specific binding elicited by DOCA was abolished by cotreatment with the mineralocorticoid receptor blockers mespirenone or ZK97894 and by cotreatment with cycloheximide. Cycloheximide 184-197 angiotensinogen Rattus norvegicus 22-28 6324149-5 1984 Ang II stimulated beta END-LI release was blocked by cycloheximide and decreased by corticosterone (5 nmol/l). Cycloheximide 53-66 angiotensinogen Rattus norvegicus 0-6 6295498-6 1982 Cycloheximide abolished the effect of angiotensin II on aldosterone production, but not on phosphatidylinositol synthesis. Cycloheximide 0-13 angiotensinogen Rattus norvegicus 38-52 6283287-4 1982 One hour pretreatment of the cells with cycloheximide, a inhibitor of protein synthesis, significantly decreased the cellular ACTH secretory response to Ang II. Cycloheximide 40-53 angiotensinogen Rattus norvegicus 153-159